- Trial phase
- Approved (FDA); supported by the ARROS-1 phase I/II pivotal trial
- Time to market
- Approved and on the market in the US (approval 2026-07-22); additional global/regulatory filings and a first-line label expansion pending
- Why 3/10
- The defining binary already passed: FDA approved Jideytro on 2026-07-22, roughly two months ahead of its original September 18, 2026 PDUFA, so there is no pending approval decision for the marketed drug; the only dated item in view is a planned second-half-2026 sNDA submission for first-line (TKI-naive) ROS1+ NSCLC, a filing event, not a regulatory decision, and Jideytro is a small niche asset inside a ~$100B mega-cap, so no hard catalyst in the next ~12 months can plausibly drive a large GSK move.
For GSK shareholders this is a strategic-validation story, not a share-price catalyst: the approval news is out, and GSK's three most recent FDA approvals (Lynavoy, Exdensur, Blenrep) were each followed by slightly negative one-day moves (avg -2.19%), consistent with a mega-cap where single drugs barely move the tape. Watch the planned 2H-2026 first-line sNDA submission and commercial uptake of Jideytro, plus sister asset neladalkib (ALK inhibitor) with its own PDUFA later in 2026, the bigger single-stock binary for the Nuvalent deal thesis.
Price Chart
Executive Summary
Jideytro (zidesamtinib) is a ROS1-targeted lung-cancer pill that the FDA approved on July 22, 2026 for previously treated ROS1-positive non-small cell lung cancer, GSK's first approved lung-cancer therapy and the first product out of its roughly $10.6 billion acquisition of Nuvalent (completed mid-July 2026). It won orphan and breakthrough-therapy designations and cleared review ahead of its original September 18, 2026 PDUFA date. For a ~$100B diversified pharma, the drug is strategically important validation of the Nuvalent deal but a small commercial niche (~50,000 ROS1-related diagnoses annually worldwide per the company's announcement), and with the approval binary already passed there is no near-term regulatory decision left to move GSK's shares.
How It Works
Zidesamtinib is an oral pill that blocks the ROS1 protein, a cancer-driving 'switch' found in a small subset of non-small cell lung cancers (NSCLC). By shutting off that switch, the drug is designed to shrink or slow tumors, including tumors that have developed resistance to earlier ROS1-targeted drugs, and it was engineered to penetrate the brain, where lung cancer commonly spreads.
Trial Status
Approval was based on the ARROS-1 phase I/II trial, with a reported objective response rate of 44% and a 12-month duration-of-response rate of 69% in previously treated ROS1-positive NSCLC; a label-expansion submission for TKI-naive (first-line) advanced ROS1-positive NSCLC is planned for the second half of 2026.
The Two-Sided Case
Upcoming Catalysts
- Planned 2H-2026 sNDA submission of zidesamtinib for TKI-naive (first-line) ROS1+ NSCLC
- Commercial launch ramp and first quarterly sales disclosures for Jideytro
- Sister Nuvalent asset neladalkib (ALK inhibitor) PDUFA/readout later in 2026, the bigger remaining binary in the deal thesis
- Any additional ex-US (e.g., EMA) filing or approval announcements
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GSK plc 6-K GSK ·Originating report